Trial Profile
PPAR alpha [peroxisome proliferator-activated receptor-alpha]: A phase 2 dose-finding and safety study for atherogenic dyslipidemia by Eli Lilly
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs LY 518674 (Primary) ; Fenofibrate
- Indications Hypercholesterolaemia; Lipid metabolism disorders
- Focus Biomarker; Therapeutic Use
- Sponsors Eli Lilly and Company
- 25 Mar 2007 Results have been published
- 06 Dec 2006 Status change
- 05 Dec 2005 New trial record.